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ABSTRACT
Sall4 is an essential transcription factor for early mammalian
development and is frequently overexpressed in cancer. Although it
is reported to play an important role in embryonic stem cell (ESC) self-
renewal, whether it is an essential pluripotency factor has been
disputed. Here, we show that Sall4 is dispensable for mouse ESC
pluripotency. Sall4 is an enhancer-binding protein that prevents
precocious activation of the neural gene expression programme in
ESCs but is not required for maintenance of the pluripotency gene
regulatory network. Although a proportion of Sall4 protein physically
associates with the Nucleosome Remodelling and Deacetylase
(NuRD) complex, Sall4 neither recruits NuRD to chromatin nor
influences transcription via NuRD; rather, free Sall4 protein regulates
transcription independently of NuRD. We propose a model whereby
enhancer binding by Sall4 and other pluripotency-associated
transcription factors is responsible for maintaining the balance
between transcriptional programmes in pluripotent cells.
KEYWORDS: Sall4, NuRD, ES cells, Enhancer, Transcription factor,
Co-repressor
INTRODUCTION
Embryonic stem cells (ESCs) have the potential to form any somatic
cell type in the adult organism; that is, they are pluripotent. In order
to properly execute lineage decisions, pluripotent cells must
precisely coordinate their gene expression programmes. To
successfully initiate differentiation down one particular lineage, a
cell must activate the gene regulatory network (GRN) appropriate to
enter that lineage, and not those corresponding to any other lineage,
while also extinguishing the pluripotency GRN. It is clear from a
large number of studies that the coordinated action of multiple
transcription factors and chromatin-modifying proteins is essential
to maintain the delicate balance between self-renewal and
differentiation of ESCs (Morey et al., 2015; Niwa, 2007; Signolet
and Hendrich, 2015). Although it is relatively straightforward to
show that a given protein plays some role in ESC differentiation,
often the precise mechanisms of how the important transcription
factors function remain ill-defined.
In this study we focus on Sall1 and Sall4, the only two members
of the spalt gene family of C2H2-type zinc-finger transcription
factors that are expressed in ESCs (reviewed by de Celis and Barrio,
2009). In humans, mutations in SALL4 show haploinsufficiency,
resulting in the autosomal dominant Okihiro/Duane-Radial Ray and
IVIC syndromes (Al-Baradie et al., 2002; Kohlhase et al., 2002;
Sweetman and Munsterberg, 2006), while mutations in SALL1 lead
to the autosomal dominant Townes-Brocks syndrome (Kohlhase
et al., 1998). SALL4 is also aberrantly expressed in many cancers
and correlates with poor prognosis, leading it to be heralded as a
new cancer biomarker and potential therapeutic target (Zhang et al.,
2015). In mice, Sall4 has been shown to play an essential role in
peri-implantation development (Elling et al., 2006; Sakaki-Yumoto
et al., 2006;Warren et al., 2007), while Sall1 is dispensable for early
embryogenesis but is essential for kidney development (Kanda
et al., 2014; Nishinakamura et al., 2001).
The role played by Sall4 in ESCs has been the subject of some
debate. Studies using Sall4 null ESCs concluded that it was
dispensable for self-renewal of ESCs, but that mutant cells were
prone to differentiate in certain conditions, indicating that it
might function to stabilise the pluripotent state (Sakaki-Yumoto
et al., 2006; Tsubooka et al., 2009; Yuri et al., 2009). By
contrast, studies in which Sall4 was knocked down in ESCs led
to the conclusion that it plays an important role in the
maintenance of ESC self-renewal (Rao et al., 2010; Zhang
et al., 2006). Sall4 was found to bind regulatory regions of
important pluripotency genes such as of Pou5f1 (previously
known as Oct4) and Nanog (Wu et al., 2006; Zhang et al., 2006)
and a physical interaction with the Pou5f1 and Nanog proteins
has been reported (Pardo et al., 2010; Rao et al., 2010; van den
Berg et al., 2010; Wu et al., 2006). The consensus arising from
these studies was that Sall4 is instrumental in the regulation of
key pluripotency genes and is thus a key regulator of the
pluripotency transcriptional network (van den Berg et al., 2010;
Xiong, 2014; Yang et al., 2010). Whether it is essential for self-
renewal remains a point of contention.
Sall1 and Sall4 have both been shown to interact biochemically
with the Nucleosome Remodelling and Deacetylase (NuRD)
complex. NuRD is a transcriptional regulatory complex that has
nucleosome remodelling activity due to the Chd4 helicase and
protein deacetylase activity due to Hdac1 and Hdac2. Additional
NuRD components are the zinc-finger proteins Gatad2a/b, SANT
domain proteins Mta1/2/3, histone chaperones Rbbp4/7, structural
protein Mbd3 (which can be substituted for by the methyl-CpG-
binding protein Mbd2) and the small Cdk2ap1 protein (Allen et al.,
2013; Le Guezennec et al., 2006). The usual interpretation of theReceived 26 April 2016; Accepted 18 July 2016
1Wellcome Trust – Medical Research Council Stem Cell Institute, University of
Cambridge, Cambridge CB2 1QR, UK. 2Department of Biochemistry, University of
Cambridge, Cambridge CB2 1QR, UK. 3Department of Molecular Biology, Faculty
of Science, Radboud Institute for Molecular Life Sciences, Radboud University,
6525 GA Nijmegen, The Netherlands. 4European Molecular Biology Laboratory
(EMBL), European Bioinformatics Institute, Wellcome Trust Genome Campus,
Cambridge CB10 1SD, UK. 5Department of Kidney Development, Institute of
Molecular Embryology and Genetics, Kumamoto University, Kumamoto 860-0811,
Japan.
*Author for correspondence (brian.hendrich@cscr.cam.ac.uk)
B.H., 0000-0002-0231-3073
This is an Open Access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution and reproduction in any medium provided that the original work is properly attributed.
3074
© 2016. Published by The Company of Biologists Ltd | Development (2016) 143, 3074-3084 doi:10.1242/dev.139113
D
E
V
E
LO
P
M
E
N
T
Sall-NuRD interaction is that Sall proteins recruit NuRD to
influence transcription of their target genes (Kiefer et al., 2002;
Kloet et al., 2015; Lauberth and Rauchman, 2006; Lu et al., 2009;
Yuri et al., 2009). The relationship between Sall proteins and NuRD
might not be so straightforward, however, as they show opposing
functions in ESCs. Whereas Sall1 and Sall4 are implicated in
maintenance of the ESC state, NuRD functions to facilitate lineage
commitment of ESCs (Kaji et al., 2006; Reynolds et al., 2012;
Signolet and Hendrich, 2015).
In this study we set out to define the function of Sall4 in ESCs and
to understand the relationship between NuRD and Sall4. We use
defined culture conditions (2i/LIF) (Ying et al., 2008) to show that
Sall1 and Sall4 prevent activation of neural genes in ESCs, but are
dispensable for the maintenance of the pluripotency GRN. We
further show that although NuRD is the major biochemical
interactor of Sall4, only ∼10% of Sall4 protein associates with
NuRD in ESCs. Despite this interaction, Sall4 neither recruits the
NuRD complex to chromatin nor shows NuRD-dependent
transcriptional regulation. The majority of Sall4 has no stable
biochemical interactors, but colocalises with pluripotency-
associated transcription factors at enhancer sequences. We
propose a model to explain why accumulation of these
transcription factors can stimulate the transcription of some genes
but inhibit the expression of others.
RESULTS
Sall4 is dispensable for ESC self-renewal, but inhibits neural
differentiation
To deﬁne the function of Sall4 in pluripotent cells, ESCs were made
homozygous for a previously described Sall4 conditional allele
(Sakaki-Yumoto et al., 2006) by two different methods: gene
targeting and derivation from homozygous Sall4 floxed mice
followed by Cre-mediated recombination. The Sall4 null ESC lines
lack exons two and three, which contain all of the zinc-ﬁnger
domains found in Sall4 (Fig. 1A). Although a truncated Sall4
transcript is produced from this allele, no protein is detectable
(Fig. S1A,B). To rule out potential compensation by the related
Sall1 protein (Yuri et al., 2009), which is the only other Sall protein
expressed in wild-type (WT) ESCs (Fig. S1A), we also derived
ESCs from Sall1flox/flox; Sall4flox/flox mice. These cells were then
used to obtain Sall1−/−; Sall4flox/− (referred to as Sall1 null) and
Sall1−/−; Sall4−/− (referred to as Sall4/1 double-null) ESC lines
(Fig. 1A,B) after Cre transfection and clonal isolation. Deletion of
either Sall1 or Sall4 had no effect on the transcription level of the
other gene (Fig. S1A). Sall1 null, Sall4 null, and Sall4/1 double-null
ESCs were viable and were able to be maintained as self-renewing
cultures in 2i/LIF conditions (Fig. S1C). All ESC lines tested (WT,
Sall1 null, Sall4 null and Sall4/1 double-null cells) were able to give
rise to tissues representing all three germ layers in teratoma assays,
indicating that Sall4 and Sall1 are dispensable for ESC potency
(Fig. 1C).
Although loss of both Sall1 and Sall4 was compatible with self-
renewal in 2i/LIF conditions, there was considerably more
spontaneous differentiation in double-mutant cultures than with
either single mutant. The Sall4/1 double-null differentiated cells
present in 2i/LIF cultures sent out long processes that stained
positively for the neuronal marker TuJ1 (also known as Tubb3),
indicative of postmitotic neurons (Fig. 1D). When plated into
serum/LIF conditions (in the absence of feeders), both Sall4 null
and Sall4/1 double-null cells showed widespread differentiation
(Fig. S1D). By contrast, Sall1 null cells behaved similarly to WT in
all conditions tested in this study.
These observations suggested that Sall4 and Sall1 are involved in
suppressing neural differentiation in ESCs. To test this hypothesis,
single- and double-mutant cultures were subjected to a standard
neuroectodermal differentiation protocol (Ying et al., 2003).
Whereas WT cultures did not produce TuJ1-expressing neurons
during the first 5 days of this protocol, TuJ1-expressing cells
displaying neuronal morphology could clearly be seen by day 5 in
Sall4 null cultures and by day 2 in the Sall4/1 double-null cultures
(Fig. 2A). After only 2 days of the protocol, the majority of Sall4/1
double-null cells had activated expression of the neural progenitor
marker Sox1, and many had extinguished Pou5f1 expression,
whereas Pou5f1 was still ubiquitously expressed in WT cells at this
point and only a fewWT cells had activated Sox1 (Fig. 2B,C). Thus,
absence of Sall proteins in ESCs results in an accelerated pace of
Fig. 1. Sall4 and Sall1 are dispensable for mouse ESC self-renewal.
(A) Schematic of targeted Sall4 and Sall1 genomic loci. Boxes represent
exons, and filled boxes indicate the coding sequence; red arrows represent
LoxP sites; purple ovals represent zinc-finger domains. (B) Western blot of
wild-type (WT), Sall4 null (hereafter Sall4 KO), Sall1 null (hereafter Sall1 KO)
and Sall4/1 double-null (hereafter Sall4/1 dKO) ESC lines in 2i/LIF. The blot
was probed with anti-Chd4, anti-Sall1, anti-Sall4, anti-Hdac1 and anti-Mta1/2
antibodies. Molecular weights are shown at left in kDa. Note that the Sall1 KO
line is heterozygous for Sall4 (Sall1−/−; Sall4flox/−). (C) Representative images
from teratoma assays of mesoderm, endoderm and ectoderm tissues derived
from WT (top) and Sall4/1 dKO. Cartilage tissue is shown for mesoderm by
H&E staining, immunofluorescence staining for Foxa2 (with DAPI) for
endoderm, and for TuJ1 (with DAPI) for ectoderm. (D) Immunofluorescence of
WT, Sall1 KO, Sall4 KO and Sall4/1 dKO ESCs grown in 2i/LIF, stained for
Pou5f1 (green), TuJ1 (white) and with DAPI (blue). Out of all DAPI-stained
Sall4/1 dKO ESCs per field, 2.09±1.19 (mean±s.d.) also stained positively for
TuJ1. Six images were used to generate counts. Scale bars: 50 µm in C;
100 µm in D.
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ESC exit from self-renewal and entry into the neural differentiation
pathway.
As loss of Sall4 is associated with accelerated differentiation,
we predicted that overexpression of Sall4 should result in
reduced ESC differentiation. To test this hypothesis, cDNAs
encoding Sall4a and Sall4b were expressed either singly or
together in a doxycycline-inducible system in WT ESCs (Fig.
S1F,G). The Sall4-overexpressing ESCs were then grown in
differentiation conditions for 96 h, prior to plating back into 2i/
LIF conditions. WT cells expressing the doxycycline-inducible
transactivator, but no cDNAs, produced very few alkaline
phosphatase-positive colonies after this procedure, indicating
that most had undergone lineage commitment (Fig. 2D). By
contrast, ESCs overexpressing Sall4 isoforms, either singly or
together, produced an increased number of alkaline phosphatase-
positive colonies, indicating that overexpression of Sall4
interferes with lineage commitment in ESCs. Further, ESCs
overexpressing Sall4 proteins showed persistent Pou5f1
expression and reduced Sox1 expression in the neural
differentiation timecourse (Fig. 2C; Fig. S1F). Together, these
experiments demonstrate that Sall proteins act to slow the pace of
neural differentiation in ESC cultures.
To test whether the Sall proteins act as general differentiation
inhibitors in ESCs, we next assessed the ability of Sall4 and
Sall4/1 mutant ESCs to differentiate towards a definitive
endoderm fate (Morrison et al., 2008). Although mutant cells
were able to silence pluripotency markers and to activate
expression of brachyury (T ), they subsequently failed to
activate the endoderm markers Sox17, Foxa2 and Cxcr4
(Fig. 2E), but neither did they show evidence for having
activated a neural programme (Fig. 2F). The failure of Sall4 null
and Sall4/1 double-null ESCs to adopt either an endodermal or
neural fate in this differentiation protocol indicates that Sall4 and
Sall1 are not general differentiation inhibitors in ESCs.
Sall4 and Sall1 prevent inappropriate activation of neural
genes in ESCs, but are not required for maintenance of the
pluripotency GRN
Sall proteins are known to be transcriptional regulators, so we
suspected that they would limit neural differentiation by controlling
gene expression. To identify the Sall4- and Sall1-dependent
transcriptional programmes during ESC self-renewal and during
early stages of neural differentiation, we measured global gene
expression profiles by RNA-seq in WT, Sall1 null, Sall4 null and
Fig. 2. Sall4 and Sall1 block neural
differentiation. (A) Representative
immunofluorescence images of WT and Sall4/1 dKO
cells after 2 days in N2B27 (left), or WT and Sall4 KO
after 5 days in N2B27 (right) stained for TuJ1 (white)
and with DAPI (blue). (B) Representative
immunofluorescence images of WT and Sall4/1 dKO
cells after 2 days in N2B27, stained with DAPI
(white) or for Sox1 (green) and Pou5f1 (magenta).
The right-hand image is a composite of Pou5f1 and
Sox1. (C) Expression of Pou5f1 and Sox1 in WT
ESCs, Sall4/1 (S41) dKO ESCs, ESCs
overexpressing (OE) Sall4a or Sall4b and their
control at day 0, 1, 2 and 3 in N2B27 was measured
by qRT-PCR. OE control refers to WT cells
expressing the Tet-transactivating factor only. OE
control and Sall4 OE cell lines were cultured in
doxycycline (DOX) for the entire timecourse.
Expression is plotted relative to housekeeping genes
as well as to their respective WT controls. Error bars
represent s.e.m. between replicates (N=3-5).
(D) Alkaline phosphatase (AP) assay of Tet-
inducible Sall4 OE cell lines. rtTA refers to the Tet-
transactivating factor. Cells were cultured for 96 h in
N2B27+DOX (or maintained in 2i/LIF conditions as a
control) before replating in 2i/LIF conditions for
5 days. Mean number of AP-positive colonies is
shown. Error bars represent s.e.m. (N=4); *P≤0.05,
one-way ANOVA followed by Dunnett’s multiple
comparisons test. Shown below is an example of
colonies produced by the indicated ESC lines either
with (below) or without (above) 96 h in differentiation
conditions. (E) Gene expression analysis across the
endoderm differentiation timecourse for the
indicated genes inWT,Sall1KO,Sall4KOandSall4/
1 dKO cells. Error bars represent s.e.m. between
replicates (N=3-9). (F) Gene expression analysis at
day 7 of the endoderm differentiation protocol in WT,
Sall1 KO, Sall4 KO and Sall4/1 dKO cells. The data
are plotted relative to the WT samples. Error bars
represent s.e.m. between replicates (N=3-9). Scale
bars: 50 µm.
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Sall4/1 double-null ESCs in self-renewing conditions (2i/LIF) and
after 48 h in differentiation conditions (N2B27) (Table S1). Global
gene expression profiles of WT, Sall1 null and Sall4 null ESCs are
largely similar in 2i/LIF conditions, resulting in replicates of these
genotypes clustering loosely together on the left-hand side of a
principal component analysis (PCA) plot (Fig. 3A). By contrast, the
double nulls show a distinct profile in the upper middle section of
the plot, consistent with increased expression of neural
differentiation markers (Fig. S2A) and the presence of
morphologically neural cells in 2i/LIF cultures of Sall4/1 double-
null cells (Fig. 1D). After 48 h in differentiation conditions
(N2B27) the WT and Sall1 null ESCs show a similar change in
gene expression profiles, moving to the lower right portion of the
plot consistent with silencing of pluripotency markers and
activation of early differentiation markers (Fig. S2A). Sall4 null
ESCs occupy a somewhat distinct location, presumably owing to
partial activation of a neural GRN (Fig. 3A; Fig. S2A). Sall4/1
double-null cells in N2B27 conditions remain at the top of the plot
but move even further to the right, consistent with more complete
adoption of a neural phenotype (Fig. S2A).
The majority of genes found to be misexpressed in either Sall1 or
Sall4 null ESCs are also misexpressed in Sall4/1 double-null ESCs,
and there is a strong correlation in the direction of the change
(Fig. S2B,C). Genes showing increased expression in Sall4 null or
Sall4/1 null cells show very high enrichment for Gene Ontology
(GO) terms involving development, including ‘neurogenesis’ and
‘nervous system development’ (Fig. S2D). Further, 42% of genes
normally upregulated in WT cells after 48 h in N2B27 are already
upregulated in Sall4/1 double-null cells in 2i/LIF, and the top GO
term associated with this group of genes is ‘nervous system
development’ (Fig. S2E). This further supports the hypothesis that
Sall4 and Sall1 act together to prevent activation of a neural gene
expression programme in ESCs.
Sall4 has been reported to be a component of the pluripotency
network, i.e. playing some role in maintaining the GRN
underpinning the pluripotent state (Dunn et al., 2014; van den
Berg et al., 2010). Findings from the analysis of expression data for
individual genes are inconsistent with such a role. Fig. 3B shows
that the expression level of many pluripotency-associated genes in
ESCs is not significantly altered in the absence of Sall4 and/or Sall1.
Although Sall4 null and Sall4/1 double-null ESCs show a reduction
in Nanog expression, and Sall4/1 double mutants also show a
reduction in levels of Sox2, this reduction does not result in
destabilisation of expression levels of the other pluripotency-
associated genes in 2i/LIF.
Although expression of pluripotency markers is largely normal,
Sall4/1 double-null ESC cultures in 2i/LIF conditions expressed
elevated levels of genes associated with neuronal differentiation
(Table S1; a subset is shown in Fig. 3C). Surprisingly, a fraction of
the Sall4/1 double-null cells in 2i/LIF conditions expressed
markers of both a neural (TuJ1) and a pluripotent (Pou5f1 or
Klf4) lineage (Fig. 1D, Fig. 3D). In order to expand on this
observation we measured gene expression levels in individual
ESCs by quantitativeRT-PCR (qRT-PCR). As expected,WTESCs
maintained in 2i/LIF conditions robustly expressed pluripotency
genes but rarely expressed neural genes (Fig. 3E). Sall4/1 double-
null ESCs showed increased expression of neural genes consistent
with RNA-seq and qRT-PCR from bulk cell populations. In
addition to aberrant expression of neural genes, individual Sall4/1
double-null ESCs simultaneously maintained the expression of
most pluripotency genes (Fig. 3E). This indicates that components
of both the pluripotency and neural differentiation GRNs can be
active simultaneously in individual Sall4/1 double-mutant ESCs.
We conclude that in ESCs Sall4 and Sall1 act to prevent activation
of neural genes, but are dispensable for maintenance of the
pluripotency GRN.
Fig. 3. Sall4 and Sall1 prevent activation of the neurogenesis
transcriptional programme but are dispensable for maintaining the
pluripotency network. (A) PCA plot representing RNA-seq data from WT,
Sall1 KO, Sall4 KO and Sall4/1 dKO cells in self-renewing (2i/LIF) or
differentiation (48 h N2B27) culture conditions. Each point represents a
separate biological replicate and each genotype is represented by two to three
independent cell lines. (B) FPKM values from RNA-seq analysis showing
expression of the indicated genes in WT, Sall1 KO, Sall4 KO and Sall4/1 dKO
cells in 2i/LIF. Error bars represent s.d. N=4-6 from two to three independent
cell lines. **P≤0.01, ****P≤0.0001, two-way ANOVA followed by a Dunnett’s
multiple comparison test. (C) Expression of example neural genes is
significantly upregulated (see supplementary Materials and Methods) in Sall4/
1 dKO compared with WT cells in 2i/LIF conditions. FPKM values relative to
WT levels are shown for all cells. N=4-6 from two to three independent cell
lines. Error bars represent s.d. (D) Example immunofluorescence images of
WT and Sall4/1 dKO cells in 2i/LIF stained with DAPI (white) and for Klf4
(magenta) and TuJ1 (green). The right-hand image is a composite of Klf4 and
TuJ1. Arrowheads indicate TuJ1-positive cells that co-express Klf4. Scale
bars: 25 µm. (E) Heatmap constructed from single ESCexpression data based
on hierarchical clustering for pluripotency-associated genes (Esrrb, Pou5f1,
Nanog, Zfp42, Klf2 and Klf4) and neural-associated genes (Sema6a, Hes5,
Nkx6.1,Sox1,Ascl1 andHes6). Individual cells are ordered from top to bottom:
the top 40 areWT cells and the bottom 35 are Sall4/1 dKO cells. Normalised Ct
values (key on the right) refer to –ΔCt values normalised to housekeeping
genes (Atp5a1, Ppia and Gapdh). Grey boxes indicate that data are not
available (N/A).
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Sall4 is an enhancer-binding protein thatcontrols expression
of developmental genes
We next sought to identify Sall4-bound genomic sequences in ESCs
using ChIP-seq. Previous studies of Sall4 binding to the ESC
genome used mouse microarrays (ChIP-Chip), the coverage of
which is heavily biased towards genes and promoters, and therefore
do not provide genome-wide coverage (Lim et al., 2008; Rao et al.,
2010; Tanimura et al., 2013; Yang et al., 2008; Yuri et al., 2009). To
facilitate immunoprecipitation of Sall4, the endogenous Sall4 locus
was targeted to add an epitope tag (Avi-3×FLAG) at the C-terminus
of the protein (Fig. S3A,B). Immunoprecipitation with an anti-
FLAG antibody verified that addition of the epitope tag did not
interfere with its known interaction with the NuRD complex (Bode
et al., 2016; Kloet et al., 2015; Yuri et al., 2009) (Fig. S3C) nor with
its intracellular localisation (Fig. S3D). To verify that addition of the
epitope tag did not interfere with normal Sall4 function, ESCs were
produced in which both Sall4 alleles were targeted with the epitope
tag. These cells did not show accelerated neural differentiation like
Sall4 null ESCs, and were able to activate endodermal genes when
subjected to the endodermal differentiation protocol, unlike Sall4
null cells (Fig. S3E-G). Thus, addition of a C-terminal epitope tag
did not detectably interfere with Sall4 function in ESCs.
Hierarchical clustering of Sall4 ChIP-seq data along with data
available in CODEX for a number of transcription factors and
histone modifications in ESCs (Sanchez-Castillo et al., 2015)
shows that the Sall4 binding profile is well correlated with those
of pluripotency-associated transcription factors such as Nanog,
Pou5f1, Esrrb and Klf4, as well as for the NuRD component
proteins Mbd3 and Chd4 (Fig. 4A,B). Further positive
correlation exists with marks of active chromatin H3K4me1,
H3K27ac and the histone acetyltransferase Ep300, but not with
H3K4me3, consistent with Sall4 associating predominantly with
enhancer sequences. Sall4 binding does not correlate with a mark
of transcribed gene bodies (H3K36me3), repressive chromatin
marks (H3K27me3, H3K9me3) or with a component of the
PRC2 complex (Ezh2).
Fig. 4. Sall4 is an enhancer-binding
protein and acts to activate as well as
inhibit gene expression. (A) Heat map
showing correlation between ChIP peaks
for the indicated histone modifications and
transcription factors in 2i/LIF. ChIP datasets
from mutant cells lines are labelled with the
antibody used for the ChIP and then the cell
line in which they were performed (i.e.
MBD3-SALL4KO refers to Mbd3 Chip in
Sall4KO cells). Mbd31 indicates Mbd3 ChIP
performed in the parent line of the Sall4 KO
and Mbd32 indicates Mbd3 ChIP performed
in the parent cell line of the Sall4/1 dKO.
Datasets used are listed in the
supplementary Materials and Methods.
(B) Heat maps of binding profiles of
H3K4me1, H3K27ac, H3K4me3, Ep300,
Mbd3, Pou5f1 and Nanog shownwithin 2 kb
of the centre of Sall4 peaks. These are
partitioned into five groups: promoter-, gene
body-, intergenic-, poised enhancer- and
active enhancer-associated peaks. Each
category is defined in the supplementary
Materials and Methods. Graphs above the
heat maps show enrichment. (C) Venn
diagram showing the overlap between
Sall4-associated genes (pink), differentially
expressed (DE) genes in Sall4 KO versus
WT (yellow) and differentially expressed
genes in Sall4/1 dKO compared with WT
(blue). All in 2i/LIF. (D) Pie chart showing the
Sall4-associated genes that are
differentially expressed in Sall4/1 dKO cells
compared with WT cells, and the numbers
that are upregulated or downregulated. All in
2i/LIF.
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To ascertain whether and how the repertoire of Sall4-bound
sequences might explain the function of Sall4 in preventing neural
differentiation, we assigned each Sall4 peak to its nearest gene. A
large proportion of Sall4-associated genes are differentially
expressed in the Sall4/1 double nulls relative to WT cells in either
2i/LIF or N2B27 conditions (40.5% and 43%, respectively; Fig. 4C,
Fig. S4A). The genes bound by Sall4 and inappropriately activated
in Sall4/1 double nulls are associated with GO terms involving
development and neurogenesis (Fig. S4B), consistent with the
crucial function of Sall4 in inhibiting neural specification being to
prevent activation of neurogenesis genes in self-renewing
conditions and during the early stages of differentiation. Globally,
Sall4 is not only a transcriptional repressor, as∼40% of Sall4-bound
and differentially expressed genes show downregulation in the
absence of Sall4 (Fig. 4D; Fig. S4C). Notably, several of the GO
terms associated with these genes are also associated with genes
showing downregulation in WT cells undergoing neural
differentiation (Fig. S2E).
NuRD is the major biochemical interactor of Sall4
To better understand how Sall4 exerts its transcriptional regulatory
activity, we identified Sall4-interacting proteins in the Sall4-FLAG
ESC line using mass spectrometry. As expected, Sall4 robustly co-
purified with the core components of the NuRD complex (Fig. 5A,
indicated in red). A number of other interacting proteins are shown in
Fig. 5A, one of which (Kpna4, an importin subunit) has previously
been identified as a NuRD interactor (Kloet et al., 2015). The
remainder are proteins normally found in the cytoplasm and/or
centriole, whereas in ESCs we find that Sall4 is strictly a nuclear
protein (Fig. S3D). Although consistent with the possibility of Sall4
interactingwith a centrosome-associatedNuRDcomplex (Sakai et al.,
2002; Sillibourne et al., 2007), these were not considered further.
Sall4-FLAG was purified at ∼14-fold excess relative to NuRD
[assuming one Mbd2/3 protein and one Sall4 protein per NuRD
complex (Kloet et al., 2015)] (Fig. 5B). As we used extraction
conditions previously shown to maintain Sall4-NuRD interactions
(Kloet et al., 2015), and the Sall4 protein that we purified was
expressed from its endogenous locus, this high ratio of Sall4 toNuRD
cannot be dismissed as an artefact of protein overexpression or
methodology. Immunoprecipitation of Chd4 from WT cells also
recovers only a fraction of the Sall4 present in the nucleus, consistent
with the majority of Sall4 not being bound to the NuRD complex
(Fig. 5C). By contrast, Sall4 immunoprecipitation recovers a large
proportion of Mbd3 present in the nucleus, which supports our
assertion that the Sall4-NuRD interaction is not being lost due to
technical reasons (Fig. 5D). Together, these data show that a relatively
minor fraction (∼7%) of Sall4 interacts with the NuRD complex,
whereas a large proportion of Mbd3-NuRD contains Sall4.
Fig. 5. Identification and stoichiometry of Sall4-
interacting proteins in ESCs. (A) Volcano plot showing
the significant interactors of Sall4 (black circles) in WT
ESCs cultured in 2i/LIF conditions. The proteins
highlighted in red are known NuRD components.
(B) Stoichiometry of NuRD components and Sall proteins
relative to Mbd2/3. Error bars represent s.d. from three
independent immunoprecipitations/mass spectrometry
replicates. (C) Western blot of immunoprecipitation with
anti-Chd4 antibody, IgG control, or 1/10 of input of nuclear
extract from WT ESCs and probed with anti-Sall4 (top) or
anti-Hdac1 (bottom) antibodies. The anti-Sall4 panel
shows a long exposure to visualise the Sall4 band in the
Chd4 immunoprecipitation (IP) lane, revealing multiple
variously SUMOylated forms of Sall4 in the input lane.
Numbers to the left indicate size markers in kDa.
(D) Western blot of immunoprecipitation with anti-FLAG
antibody, IgG control, or 1/10 of input of nuclear extract
from Sall4-FLAG ESCs and probed with the antibodies
indicated at right. The anti-FLAG immunoprecipitations are
shown with and without the general nuclease benzonase,
which makes no difference to the Nanog or Mbd3
association. Size markers are shown on the left in kDa.
(E) Volcano plot showing the significant interactors of Sall4
(black circles) in Mbd3 KO ESCs cultured in 2i/LIF
conditions. The proteins highlighted in red are known
NuRD components.
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Sall4-FLAG purification was repeated in ESCs lacking Mbd3, a
major structural NuRD component protein (Kaji et al., 2006;
Reynolds et al., 2012), to identify NuRD-independent interactors of
Sall4. Purification of Sall4 and associated proteins in Mbd3 null
ESCs again yielded NuRD components (but no Mbd3), which
presumably derive from the small amount of Mbd2-NuRD present
in these cells (Fig. 5E). In addition to NuRD components, the only
significant interacting protein was the Non-POU domain-containing
octamer-binding protein Nono, which was not identified in WT
cells. Nonowas purified at extremely low levels and is unlikely to be
a significant interacting protein.
The pluripotency-associated factors Pou5f1 and Nanog have
previously been reported to co-purify with overexpressed Sall4
protein in ESCs grown in serum/LIF conditions (van den Berg et al.,
2010), and the endogenous proteins have been shown to interact by
immunoprecipitation (Rao et al., 2010; van den Berg et al., 2010;
Wu et al., 2006). Although we did identify Pou5f1 peptides in our
experiment, these were very few and far below significance
(Fig. S5A). Although no Nanog peptides were identified in our
mass spectrometry experiments, wewere able to detect an interaction
between Sall4 and Nanog protein by immunoprecipitation of our
tagged Sall4 and western blotting (Fig. 5D). Only a very small
proportion of the endogenous nuclear Nanog protein was found to
associate with Sall4, which presumably represents a weak and/or
infrequent interaction that is below the minimum threshold of
detection for mass spectrometry with endogenous Sall4.
We conclude that an interaction between Sall4 protein and
pluripotency factors is detectable, and may rise above background
in mass spectrometry experiments using overexpressed Sall4
protein, but involves a very small proportion of total endogenous
Sall4 protein and thus does not represent a major interaction. Thus,
although ∼7% of Sall4 protein is found within the NuRD complex,
the majority of Sall4 protein in ESCs does not appear to stably
associate with any other protein, but may associate transiently or
infrequently with pluripotency-associated transcription factors.
Sall4 neither recruits nor functions through the NuRD
complex
Given that a large proportion of NuRD contains Sall4, and that
Sall4 and Mbd3 co-occupy a number of genomic sites, the
standard model of transcription factor–co-repressor interaction
stipulates that Sall4 should recruit NuRD to effect transcriptional
repression. If this were true, we would expect that Sall4- and
Mbd3-associated genes should show similar changes in expression
in Sall4/1 double-null ESCs as in Mbd3 null ESCs. Of all Sall4-
bound genes showing differential expression in Sall4/1 double-
null ESCs, 20% (315 of 1527 genes) were also bound by Mbd3
and showed transcriptional changes in Mbd3 null ESCs (Fig. 6A).
There is no correlation (neither positive nor negative) in the
direction of gene expression changes between Mbd3 null and
Sall4/1 double-null cells for these 315 genes (Fig. 6B), making it
very unlikely that they are co-regulated by Sall4 and NuRD.
Similarly, those genes misexpressed in Sall4/1 or Mbd3 mutant
cells in differentiation conditions (N2B27) show no correlation in
terms of the direction of gene expression change (Fig. S6B).
Therefore, our analysis provides no evidence that Sall4 and NuRD
act in concert to regulate gene expression.
If Sall4 acts to recruit NuRD to specific sites, then we would
expect that many Mbd3- and Sall4-bound regions would show loss
of Mbd3 binding in Sall4 null ESCs. Of 4422 Mbd3 peaks lost in
Sall4 null cells, 24% (1073) were bound by Sall4 inWT cells, while
20% of the Mbd3 peaks lost in Sall4/1 double-null cells were Sall4-
bound sites (Fig. 6C; Fig. S6C). This amounts to 7.3% of all Mbd3
sites that could be recruited by Sall4, corresponding to less than 5%
of genes misregulated in the Mbd3 nulls, yet the transcriptional
changes seen at these genes inMbd3 null ESCs do not correlate with
those seen in Sall4/1 double-null cells (Fig. S6D). If the same
analysis is performed using a less stringent method of defining
peaks from ChIP replicates (i.e. by merging replicates rather than
using the IDR method; see Materials and Methods), then 3.0%
of Mbd3 peaks show both Sall4 dependency and Sall4 binding
(Fig. S6E). Thus, we find no evidence to support a model whereby
Sall4 directs the recruitment of NuRD to control gene expression in
ESCs.
Sall4 occupies enhancers with pluripotency-associated
transcription factors to regulate transcription
Although Sall4 does not dictate NuRD chromatin targets,
surprisingly, NuRD was found to influence the genome-wide
distribution of Sall4. ChIP-seq for Sall4-FLAG in Mbd3 null cells
identified 3.5-fold more Sall4-bound locations than in WT cells
(17,739 versus 5062; Fig. 6D). The Sall4-bound sites found only in
Mbd3 null cells predominantly consisted of enhancers, as is seen for
the WT cohort of Sall4-bound sites (Fig. S6F). In addition to Sall4
binding to novel sites in the absence of Mbd3/NuRD (e.g. Tex13 and
Ppp2r2c enhancers; Fig. S7A,B), Sall4 also shows increased binding
at some peaks seen in WT cells (e.g. Nanog, but not Pou5f1;
Fig. S7A,B). This indicates that more Sall4 protein is available to
bind chromatin in the absence of Mbd3. Indeed, Mbd3 null ESCs
contain moderately (2- to 3-fold) increased levels of Sall4 protein,
despite there being no increase in Sall4 transcript levels (Table S1,
Fig. S5B).
By focusing on the Sall4-enriched regions seen only inMbd3 null
ESCs, we were able to investigate the consequences of novel Sall4
binding to enhancer sequences. In Mbd3 null cells, they not only
gain Sall4 protein enrichment but also become enriched for the
pluripotency-associated transcription factors Pou5f1, Nanog, Klf4
and Esrrb (Fig. 6E). Notably, no increase in Chd4 protein
enrichment is seen at these same sites in the Mbd3 null cells,
indicating that the observed increase in transcription factor
association is not simply a consequence of these sites becoming
generally more accessible. What consequence does recruitment of
transcription factors have on these enhancers? Assigning these sites
to their nearest genes identifies 6666 genes, of which nearly one-
fifth (1166) show a significant gene expression change inMbd3 null
ESCs (Fig. S7C), with approximately equal numbers showing
increased or decreased expression (Fig. S7D). These sites are not
associated with significant Mbd3 enrichment in WT cells (Fig. 6D),
yet they account for nearly one-third (1166/4049) of all genes
misexpressed in Mbd3 null ESCs (Fig. S7C).
Recruitment of Sall4 and four pluripotency-associated
transcription factors to these enhancers is equally likely to result
in gene activation as it is in repression. GO terms associated with
upregulated genes involve development and motility (Fig. S7E),
whereas genes showing decreased expression do not significantly
associate with any specific GO term. Thus, enhancers able to
increase transcription in response to the recruitment of this group
of transcription factors are predominantly associated with
developmental genes, whereas enhancers associated with other
kinds of genes are not activated by these transcription factors, and
indeed this recruitment interferes with transcription. In summary,
we propose that Sall4 acts to prevent neural differentiation of ESCs
by binding to enhancers along with other pluripotency-associated
transcription factors, where their presence interferes with gene
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activation (Fig. 7). At other enhancers, binding of this same cohort
of transcription factors increases transcription.
DISCUSSION
Sall4 is an essential protein for early mammalian development.
Here, we show that Sall4 and Sall1 function to prevent activation of
neural development genes in ESCs, but are not required to maintain
the pluripotent state. Sall4 is predominantly an enhancer-binding
protein and, although it binds to a similar array of genomic locations
as the pluripotency-associated proteins Pou5f1, Nanog, Esrrb and
Klf4, it does not stably associate with these proteins. We further
clarify the nature of the relationship between Sall4 and the NuRD
complex. Although a proportion of Sall4 protein does stably interact
with the NuRD complex, contrary to the standard model of co-
repressor recruitment to DNA, Sall4 neither recruits NuRD to
specific sites on DNA nor does it use NuRD to control expression of
its target genes. Rather, Sall4 occupancy of enhancer sequences,
along with other pluripotency-associated transcription factors, can
either enhance or interfere with transcription, depending upon the
target gene (Fig. 7).
Previous studies of Sall4 function in ESCs have produced
conflicting conclusions about the role of Sall4 in ESC self-renewal
(Rao et al., 2010; Sakaki-Yumoto et al., 2006; Tsubooka et al., 2009;
Yuri et al., 2009; Zhang et al., 2006). It is very likely that the differing
results obtained from these various laboratories are heavily
influenced by the different culture conditions. Using a fully
defined culture system [2i/LIF (Ying et al., 2008)] we show that
Sall4 and Sall1 are dispensable for ESC self-renewal, but that they
prevent premature activation of neural genes. This result agreeswith a
report that knockdown of Sall4 in 2i/LIF conditions does not
significantly compromise ESC self-renewal (Dunn et al., 2014), and
with our finding that Sall4 overexpression inWT cells inhibits neural
differentiation (Fig. 2C). Notably, Yuri et al. (2009) were able to
establish Sall4/1-double-knockout ESCs in serum/LIF conditions,
indicating that this is not a difference in Sall4 function between
different culture conditions. We show clearly that Sall4 is not an
essential pluripotency factor, but rather is a differentiation inhibitor.
We speculate that interference with Sall protein activity might
enhance the efficiency of directed pluripotent cell neural
differentiation protocols for disease modelling or regenerative
medicine applications.
Using mass spectrometry on immunoprecipitated endogenous
Sall4 protein, we find that ∼7% of nuclear Sall4 protein interacts
with the NuRD complex. The simplest interpretation of this would
Fig. 6. Sall4 neither recruits nor acts through the
NuRD complex. (A) Venn diagram showing the
overlap between genes associated with overlapping
Sall4 and Mbd3 peaks in 2i/LIF (pink), genes
associated with a Sall4 peak and differentially
expressed in Sall4/1 dKO in 2i/LIF (blue), and genes
differentially expressed in Mbd3 KO cells in 2i/LIF
(yellow). (B) Plot comparing the log2 fold change
between differentially expressed genes in bothSall4/1
dKO and Mbd3 KO cells compared with WT cells.
These genes have Sall4 andMbd3 overlapping peaks
and are differentially expressed inSall4/1 dKO cells as
well as in Mbd3 KO cells compared with WT, all in
2i/LIF (i.e. the 315 genes shown in grey in A). A linear
regression was performed to generate the R-square
value. (C) Venn diagram showing overlap between
Mbd3 peaks in WT cells (pink), Mbd3 peaks in Sall4
KO cells (blue) and Sall4 peaks in WT cells (yellow).
The WT used for this comparison is the parent line of
the Sall4 KO cells. All are in 2i/LIF. (D) Venn diagram
showing the overlap of Sall4 peaks in WT cells (pink)
with Sall4 peaks in Mbd3 KO cells (blue) and Mbd3
peaks inWT cells (yellow). (E) ChIP-seq heat maps of
2 kb either side of the Sall4 peaks only found inMbd3
KO ESCs and not normally bound by Mbd3 (bold
black outline in D) for the indicated transcription
factors in WT and Mbd3 KO ESCs.
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be that this subset of Sall4 indirectly influences gene expression by
recruiting NuRD to specific sequences. The problem with this
scenario is that Sall4 and NuRD serve opposing functions in ESCs:
NuRD facilitates exit of ESCs from the self-renewing state by
restricting expression levels of pluripotency-associated genes
(Reynolds et al., 2012), whereas Sall4 acts to prevent activation of
neural genes and precocious neural specification in ESCs (Fig. 2).
This is not what one would expect if NuRD collaborates with Sall4
to regulate the expression of Sall4 target genes. We find no evidence
that Sall4 plays any significant role in recruiting NuRD to
chromatin, nor that the expression levels of Sall4 target genes are
sensitive to the presence or absence of NuRD.
We identified neither Nanog nor Pou5f1 as a significant Sall4-
interacting protein in our proteomics experiments, although a weak
interaction could be detected by immunoprecipitation and western
blotting (Fig. 5D). Both of these proteins have been identified as
Sall4 interactors in other studies (Rao et al., 2010; van den Berg
et al., 2010; Wu et al., 2006). Our study differs from previous
studies of Sall4 interactors as we have incorporated an epitope tag
to the endogenous Sall4 locus, and therefore have not introduced an
extra copy of Sall4 into ESCs. Sall4 dosage is important in somatic
tissues (Koshiba-Takeuchi et al., 2006; Sakaki-Yumoto et al.,
2006), so introduction of more Sall4, even if expressed at levels
comparable to endogenous protein, would increase the
concentration of nuclear Sall4 and might enable association with
proteins such as Pou5f1 and Nanog (Fig. 7). Our results do not
preclude an interaction between Sall4 and these pluripotency
factors, but rather suggest that such interactions are either transient
or involve only a minor fraction of total Sall4.
The Sall4 protein does not appear to have any enzymatic activity,
does not recruit the NuRD complex to its sites of action, and does not
have any other major, stably interacting proteins. Sall4 is
predominantly found at enhancers, which are also often bound by
pluripotency-associated transcription factors such as Pou5f1,
Nanog, Klf4 and Esrrb (Fig. 4A,B, Fig. 7). Loss of Sall4 results in
increased transcription of some Sall4-associated genes and reduced
transcription of others, indicating that the outcome of Sall4 activity
depends upon the sequence to which it binds (Fig. 7). We propose
that accumulation of these transcription factors at enhancers that
normally respond to lineage-specific transcription factors interferes
with their activation, possibly by steric hindrance of transcription
factor binding (Fig. 7A). In cells lacking the Sall proteins, this
accumulation of transcription factors at neural genes does not occur
and permits gene activation (Fig. 7B). By contrast, binding of these
proteins to enhancers of genes normally expressed during ESC self-
renewal promotes or enforces active transcription (Fig. 7C),
although maintaining expression of pluripotency-associated genes
does not strictly require the presence of Sall4. This scenario is
similar to that seen for Pou5f1 during reprogramming, where
Pou5f1 binding to enhancers of somatic genes in mouse embryonic
fibroblasts correlates with transcriptional silencing of the associated
gene, whereas Pou5f1 binding to enhancers of genes normally
expressed in pluripotent cells correlates with activation (Chen et al.,
2016). This would also mean that the dosage of Sall4 would be very
important: too little Sall4 and some genes might be activated
inappropriately, while too much Sall4 could interfere with the
expression of lineage-appropriate genes. This could explain the
observed haploinsufficiency of Sall4 during mammalian
Fig. 7. Model of Sall4 activity in ESCs. (A) Sall4
binds to the enhancer of a gene normally
expressed during neural development along with
Nanog, Pou5f1, Klf4 and Esrrb, preventing the
association of a lineage-specific transcription
factor (differentiation factor). The result is failure to
activate the neural gene. (B) In the absence of
Sall4 and Sall1 the differentiation factor is no
longer prevented from binding to the enhancer
and the neural gene is then inappropriately
activated. (C) At enhancers of genes normally
expressed in undifferentiated ESCs the binding of
Sall proteins along with Pou5f1, Nanog, Klf4 and
Esrrb maintains transcriptional activation of the
self-renewal gene.
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development (Koshiba-Takeuchi et al., 2006; Sakaki-Yumoto et al.,
2006).
MATERIALS AND METHODS
Mouse ESC lines, culture and manipulation
All ESC lines were cultured in 2i/LIF conditions on gelatin-coated
plates. ESC derivations were performed in 2i/LIF conditions. Gene
targeting was carried out using homologous recombination methods and
verified by long-range PCR, RT-PCR and western blotting. For details,
including the antibodies used, see the supplementary Materials and
Methods. Doxycycline treatment with alkaline phosphatase staining, the
neural differentiation protocol and teratoma assay were performed as
detailed in the supplementary Materials and Methods. All animal
experiments were approved by the Animal Welfare and Ethical Review
Body of the University of Cambridge and carried out under appropriate
UK Home Office licenses.
Chromatin immunoprecipitation and sequencing
ChIP-seq in ESCs was performed as previously described (Reynolds et al.,
2012). For details, including the antibodies used, see the supplementary
Materials and Methods.
Bioinformatic analyses
Sall4-FLAG, Mbd3 and Chd4 ChIP-seq data were analysed using the
irreproducible discovery rate (IDR) method, which assesses replicate
agreement and therefore only calls peaks that are strong in all replicates
(Landt et al., 2012; Li et al., 2011). This has the effect of removing false
positives, but also of removing many weaker true positives. Thus, the set of
‘bound’ peaks used in the subsequent analyses is not comprehensive, but is
of very high confidence and will represent only the strongest-bound peaks.
Differentially expressed genes are listed in Table S1, and genes closest to
Sall4 and Mbd3 peaks are listed in Table S2. For full details, see the
supplementary Materials and Methods.
Mass spectrometry
To identify Sall4 interactors, tryptic peptides obtained from affinity-purified
nuclear proteins were subject to mass spectrometry analysis and LFQ
peptide identification as described in the supplementary Materials and
Methods.
qRT-PCR
Single-cell expression analysis of pluripotency and lineage markers was
performed by qRT-PCR using the TaqMan primers described in the
supplementary Materials and Methods.
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